Navigation Links
ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference
Date:5/4/2010

fering the possibility of maintaining remission without the serious complications associated with the current standard of care.  Additionally, these data provide a powerful validation of targeting the chemokine system to treat major inflammatory and autoimmune diseases."

Results for PROTECT-1 Maintenance Period of Study

Over the course of the Maintenance period, the remission rate in the Traficet-EN group remained between 47% and 50%, whereas the remission rate continued to decrease in the placebo group. At week 36, 47% of subjects in the Traficet-EN group were in remission compared to 31% in the placebo group (p=0.01). Furthermore, at week 36, 41% of patients in the Traficet-EN group were in corticosteroid-free remission compared to 28% in the placebo group (p=0.04).

Study Design for PROTECT-1 Trial

This randomized, placebo-controlled, double-blind clinical trial of 436 patients was comprised of three discrete periods which allowed for evaluation of efficacy and safety of Traficet-EN in inducing a clinical response or remission, as well as maintaining response/remission in Crohn's disease over a combined total of 12 months. The 12-week Induction period of the study was followed by a 4-week, open-label period, during which all subjects received Traficet-EN. Patients who achieved a pre-specified 70-point or greater reduction in CDAI were re-randomized to active drug or placebo for an additional 36-week Maintenance period, thereby permitting an evaluation of the drug's ability to maintain a treatment response. CDAI is a research tool used for determining a patient's level of disease activity and is the key measure regarded by regulatory agencies as an appropriate endpoint to assess the efficacy of a drug for the treatment of Crohn's disease.

About Traficet-EN™ (CCX282-B)


'/>"/>
SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. Spherix Reports Second Quarter Earnings
10. Tapestry Reports Second Quarter 2007 Results
11. Callisto Reports on Second-Quarter 2007 Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Celsion Corporation (the "Company") (NASDAQ: CLSN ... institutional investors to purchase an aggregate of approximately $15 ... registered direct offering, led by a dedicated health care ... agreements with these investors pursuant to which the Company ...
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
(Date:1/15/2014)... an unprecedented effort to curb the spread of "superbugs" such as ... an advanced and portable UV germicidal lamp manufactured by MRSA-UV is ... In order to prevent EMS paramedics and transport patients ... Palm Beach Fire Rescue is the first in the ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
... Small Molecules ... NEW YORK, Aug. 7 Historically, bile acids ... the absorption of,dietary lipids and cholesterol homeostasis. However, ... broader systemic endocrine,functions, acting as important mediators of ...
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) reported today financial ... 30, 2008 and provided an update,on the Company,s progress ... quarter and six month period ended June 30, 2008, ... the United,States (GAAP), was $14.1 million and $28.7 million, ...
Cached Medicine Technology:Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling 2Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling 3Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 2Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 3Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 4Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 5Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 6Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 7Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 8Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 9Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 10Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 11
(Date:4/17/2014)... chronic inflammation in benign prostate tissue was associated ... association was found even in those with low ... published in Cancer Epidemiology, Biomarkers & Prevention ... Cancer Research. , An analysis of prostate tissue ... arm of the Prostate Cancer Prevention Trial (PCPT) ...
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... 17, 2014U.S. military personnel who served in Iraq ... traumatic brain injury (TBI) were compared to military ... medical reasons. Differences in measures of overall disability, ... after injury are reported in an article in ... from Mary Ann Liebert, Inc., publishers. The article ...
(Date:4/17/2014)... about one in five infants in the United States ... first several months after birth. Research into probiotic use ... the April 1, 2014 issue of the British ... study, "Probiotics and Infant Colic," concluding that the use ... colic did not reduce crying or fussing in ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... by conservative political operative with ties to convicted lobbyist Jack ... Action Fund issued a new investigative report today called "Viewers ... the political ads running in eight states, including Virginia, to ... Americans for Prosperity Foundation, which has a record as a ...
... found some also suffer PTSD years after treatment , ... survivors aren,t following recommended guidelines on screenings for second ... suffer from post-traumatic stress disorder years after beating their ... guidelines can be costly because childhood cancer survivors are ...
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today announced ... Administration (FDA) that the Dermatologic and Ophthalmic Drugs Advisory Committee ... ophthalmic solution) on June 26, 2009. , , On ... with the FDA for Bepreve as an eye drop treatment ...
... Minnesota has become the first state in the nation ... providers to electronically submit insurance claims to health plans, ... referred to as the E3 Initiative, will also require ... eligibility for insurance coverage and benefits, as well as ...
... U.S.A. (June 1st, 2009) ChemGenex Pharmaceuticals Limited ... its pivotal study of omacetaxine in patients with ... of an oral presentation and discussion today at ... Annual Meeting in Orlando, Florida. The open label ...
... Senators Arlen Specter (D-Pa.) and John Cornyn (R-Tex.) will ... equipment and services during the American Association for Homecare ... Hilton. , , During the week, ... institute fundamental reforms to Medicare policy for durable medical ...
Cached Medicine News:Health News:'Viewers Beware' Report by Watchdog Group Exposes Conservative Group Behind Anti-Healthcare Ads Running in Virginia 2Health News:Many Childhood Cancer Survivors Not Checking for Second Malignancies 2Health News:Many Childhood Cancer Survivors Not Checking for Second Malignancies 3Health News:ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis 2Health News:ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis 3Health News:Minnesota Health Plans Select IGI and ORBIT(R) to Power First State-Mandated Shift to Standardized, Electronic Data Exchange between Plans and Providers 2Health News:Minnesota Health Plans Select IGI and ORBIT(R) to Power First State-Mandated Shift to Standardized, Electronic Data Exchange between Plans and Providers 3Health News:ChemGenex's omacetaxine may provide first viable treatment option for highly resistant form of CML 2Health News:Senators Arlen Specter and John Cornyn Will Discuss Medicare Issues at American Association for Homecare Legislative Conference, June 2-3, 2009 2Health News:Senators Arlen Specter and John Cornyn Will Discuss Medicare Issues at American Association for Homecare Legislative Conference, June 2-3, 2009 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: